Nebenwirkungen · Stivarga
Stivarga 40 mg film-coated tablets. · Abschnitt 4.8 · PDF-Seite 11–12
HOS-127112 · Präparat HOS-096369
11 System Organ Class Very common Common Uncommon Rare Not known (MedDRA) Musculo- Muscle skeletal and spasms connective tissue disorders Renal and Proteinuria urinary disorders General Asthenia/ disorders and fatigue administration Pain*** site Fever conditions Mucosal inflammation Investigations Weight loss Increase in amylase Increase in lipase Abnormal Inter- national normalised ratio * fatal cases have been reported ** palmar-plantar erythrodysesthesia syndrome in MedDRA terminology ***Most frequently reported types of pain (≥10%) are abdominal pain and back pain # according to drug-induced liver injury (DILI) criteria of the international DILI expert working group
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:26:00Z · SHA-256 188477d5802aa3c29bbcc6435c9e581d56ccf3178a537b51e23d7bce8cf4f8be · Passage a533e23fadd2ff11381a657602c3f746541d94bde1992d305bcf864859f3dc39 · Zeichen 6025–7238 im Abschnitt